Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sergio J Dubner

Showing results (11-20 of 28) with videos related to

Pageof 3
Sort By:
The American Journal of Medicine|April 15, 2018
Gender Differences in Antithrombotic Treatment for Newly Diagnosed Atrial Fibrillation: The GLORIA-AF Registry ProgramMichał Mazurek, Menno V Huisman, Kenneth J Rothman, et al.
Journal of Arrhythmia|June 13, 2020
Stroke prevention in atrial fibrillation changes after dabigatran availability in China: The GLORIA-AF registryChangsheng Ma, Lionel Riou França, Shihai Lu, et al.
Journal of the American College of Cardiology|February 18, 2017
The Changing Landscape for Stroke Prevention in AF: Findings From the GLORIA-AF Registry Phase 2Menno V Huisman, Kenneth J Rothman, Miney Paquette, et al.
American Heart Journal|March 1, 2014
Design and rationale of Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation: a global registry program on long-term oral antithrombotic treatment in patients with atrial fibrillationMenno V Huisman, Gregory Y H Lip, Hans C Diener, et al.
Clinical Research in Cardiology : Official Journal of the German Cardiac Society|March 16, 2022
Dabigatran versus vitamin K antagonists for atrial fibrillation in clinical practice: final outcomes from Phase III of the GLORIA-AF registryMenno V Huisman, Christine Teutsch, Shihai Lu, et al.
Thrombosis and Haemostasis|December 7, 2017
Regional Differences in Antithrombotic Treatment for Atrial Fibrillation: Insights from the GLORIA-AF Phase II RegistryMichał Mazurek, Menno V Huisman, Kenneth J Rothman, et al.
American Heart Journal|April 15, 2018
Two-year follow-up of patients treated with dabigatran for stroke prevention in atrial fibrillation: Global Registry on Long-Term Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) registryMenno V Huisman, Kenneth J Rothman, Miney Paquette, et al.
Journal of the American College of Cardiology|September 23, 2017
Persistence With Dabigatran Therapy at 2 Years in Patients With Atrial FibrillationMiney Paquette, Lionel Riou França, Christine Teutsch, et al.
The American Journal of Cardiology|December 2, 2019
Dabigatran Persistence and Outcomes Following Discontinuation in Atrial Fibrillation Patients from the GLORIA-AF RegistryMiney Paquette, Lionel Riou França, Christine Teutsch, et al.
American Heart Journal|December 7, 2019
Safety and effectiveness of dabigatran at 2 years: Final outcomes from Phase II of the GLORIA-AF registry programMichał Mazurek, Christine Teutsch, Hans-Christoph Diener, et al.
Pageof 3

Showing results (11-20 of 28) with videos related to

Sort By:
Pageof 3
The American Journal of Medicine|April 15, 2018
Gender Differences in Antithrombotic Treatment for Newly Diagnosed Atrial Fibrillation: The GLORIA-AF Registry ProgramMichał Mazurek, Menno V Huisman, Kenneth J Rothman, et al.
Journal of Arrhythmia|June 13, 2020
Stroke prevention in atrial fibrillation changes after dabigatran availability in China: The GLORIA-AF registryChangsheng Ma, Lionel Riou França, Shihai Lu, et al.
Journal of the American College of Cardiology|February 18, 2017
The Changing Landscape for Stroke Prevention in AF: Findings From the GLORIA-AF Registry Phase 2Menno V Huisman, Kenneth J Rothman, Miney Paquette, et al.
American Heart Journal|March 1, 2014
Design and rationale of Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation: a global registry program on long-term oral antithrombotic treatment in patients with atrial fibrillationMenno V Huisman, Gregory Y H Lip, Hans C Diener, et al.
Clinical Research in Cardiology : Official Journal of the German Cardiac Society|March 16, 2022
Dabigatran versus vitamin K antagonists for atrial fibrillation in clinical practice: final outcomes from Phase III of the GLORIA-AF registryMenno V Huisman, Christine Teutsch, Shihai Lu, et al.
Thrombosis and Haemostasis|December 7, 2017
Regional Differences in Antithrombotic Treatment for Atrial Fibrillation: Insights from the GLORIA-AF Phase II RegistryMichał Mazurek, Menno V Huisman, Kenneth J Rothman, et al.
American Heart Journal|April 15, 2018
Two-year follow-up of patients treated with dabigatran for stroke prevention in atrial fibrillation: Global Registry on Long-Term Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) registryMenno V Huisman, Kenneth J Rothman, Miney Paquette, et al.
Journal of the American College of Cardiology|September 23, 2017
Persistence With Dabigatran Therapy at 2 Years in Patients With Atrial FibrillationMiney Paquette, Lionel Riou França, Christine Teutsch, et al.
The American Journal of Cardiology|December 2, 2019
Dabigatran Persistence and Outcomes Following Discontinuation in Atrial Fibrillation Patients from the GLORIA-AF RegistryMiney Paquette, Lionel Riou França, Christine Teutsch, et al.
American Heart Journal|December 7, 2019
Safety and effectiveness of dabigatran at 2 years: Final outcomes from Phase II of the GLORIA-AF registry programMichał Mazurek, Christine Teutsch, Hans-Christoph Diener, et al.
Pageof 3